Award
National Eye Institute 1R41EY039138-01
OutFlowGen: One-Time CRISPR Therapy for Glaucoma
Recipient
OutFlowGen LLC
Award Amount
$311,049.00
Ceiling
$311,049.00
Awarded
July 17, 2026
Identifier
1R41EY039138-01
Award for developing a one-time CRISPR/Cas9 gene editing therapy for glaucoma to lower intraocular pressure and improve patient adherence, managed by the National Eye Institute with a budget of $311,049 for fiscal year 2026.
Description
The project involves developing a one-time, non-viral lipid nanoparticle gene editing therapy for glaucoma using CRISPR/Cas9 technology. The project aims to lower intraocular pressure and improve patient adherence by providing a durable treatment. The project emphasizes innovative gene delivery and editing techniques in ocular tissues.